High Selectivity

Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ.  A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.  Blood. 2005 Nov 1; 106 (9): 3035-42.

Huang L, Reekmans G, Saerens D, Friedt JM, Frederix F, Francis L, Muyldermans S, Campitelli A, Van Hoof C.  Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays.  Biosens Bioelectron. 2005 Sep 15; 21(3):483-90.

Gibbs WW.  Nanobodies.  Sci Am. 2005 Aug; 293 (2): 78-83.

Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, Conrath K.  Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen.  J Biol Chem. 2004 Dec 10; 279 (50): 51965-72.

Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H.  Efficient cancer therapy with a nanobody-based conjugate.  Cancer Res. 2004 Apr 15; 64 (8): 2853-7.

Muyldermans S.  Single domain camel antibodies: current status.  J Biotechnol. 2001 Jun; 74 (4): 277-302.

Lauwereys M, Ghahroudi MA, Desmyter A, Kinne J, Hölzer W, De Genst E, Wyns L, Muyldermans S.  Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.  EMBO J. 1998 Jul 1; 17(13): 3512-20.

 < back